Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DR26F9AF4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $43,493
Award facts
- Contract value 100% obligated
- $43,493.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $43,493.10 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on November 5, 2025, with completion scheduled for November 6, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis, making it a critical specialty pharmaceutical supply for military healthcare systems. The contract was fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters.
This delivery order falls under AmerisourceBergen's comprehensive $999,999,999 indefinite delivery contract with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor, AmerisourceBergen supports multiple federal healthcare customers including the Defense Health Agency and U.S. Coast Guard through this flexible contract mechanism, which enables rapid procurement of a broad range of specialty medications, brand-name and generic drugs, and medical supplies across numerous therapeutic domains. The absence of a set-aside designation indicates this award was made through open competition, reflecting the contractor's capability to meet federal procurement standards.
Quick answers
Who was awarded contract SPE2DR26F9AF4?
SPE2DR26F9AF4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DR26F9AF4 worth?
The government has obligated $43,493 on SPE2DR26F9AF4.
Is contract SPE2DR26F9AF4 an order under another contract?
Yes. SPE2DR26F9AF4 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9AF4 competed?
The extent of competition for SPE2DR26F9AF4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award